American Cancer Society opens COVID-19 tracking study

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The American Cancer Society is inviting participants to join its ongoing Cancer Prevention Study 3 (CPS-3) to use a new app to help investigators track the COVID-19 epidemic and inform future research efforts.

The app, the COVID Symptom Tracker, was created by doctors and scientists at the Harvard T.H. Chan School of Public Health, Massachusetts General Hospital, King’s College London, and Stanford University School of Medicine, working in partnership with the health science company ZOE. It is available to anyone in the United States or United Kingdom.

Participants of the study are asked to download the app and track whether they feel any symptoms each day.

The goal of the app is to:

  • Better understand symptoms of COVID-19,

  • Evaluate how fast the virus is spreading in different areas,

  • Identify high-risk areas in the country,

  • Identify who is most at risk by better understanding symptoms linked to health conditions; and

  • Identify the exposure of healthcare workers to COVID-19.

“By inviting CPS-3 participants to use this app, we hope to be able to help address the immediate and long-term needs of cancer patients and survivors,” Alpa Patel, senior scientific director, epidemiology research and lead investigator for CPS-3, said in a statement. “In the short term, data gathered from the app will help characterize the progression of symptoms and trajectories related to coronavirus. Over time, the data can be combined with CPS-3 data to study the longer-term health effects related to infection, including in vulnerable populations like cancer survivors.”

The Cancer Prevention Study includes more than 300,000 participants from 35 states and Puerto Rico who completed a comprehensive baseline survey that included extensive medical, lifestyle, and other information. Participants are contributing to a better understanding of the roles of lifestyle, genetic, and other factors in cancer.

COVID-19 Tracker can be used with other major studies, including the Nurses’ Health Study, one of the largest and longest-running scientific studies in the world with 280,000 participants, many of whom are active health care workers treating people with COVID.

Table of Contents

YOU MAY BE INTERESTED IN

On Feb. 19, GRAIL Inc. announced that its pivotal NHS-Galleri trial failed to meet its primary endpoint of reduction in advanced stage cancers. The media and the market reacted as one would expect: GRAIL’s stock price halved the day after the announcement and at least three law firms said that they are conducting investigations in preparation for filing investor suits.
If you listen to GRAIL executives discuss the results of the long-awaited trial of the company’s multicancer detection test, you might be led to conclude that the company’s pivotal NHS-Galleri study had an overwhelmingly positive result.
Undeterred by the negative topline result of its pivotal trial of Galleri, a multicancer detection test, the test’s sponsor, GRAIL, said it’s forging ahead with its plan to get FDA approval and reimbursement from CMS and private insurers.
Philip E. Castle, director of the NCI Division of Cancer Prevention, said he was disappointed to hear that GRAIL’s NHS-Galleri trial did not meet its primary endpoint of reduction in late-stage cancers.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login